Cancer News and Research

Latest Cancer News and Research

No increased risk of childhood cancer if born near mobile phone stations: Study

There have been concerns regarding increased risk for cancer in children born to mothers who lived near mobile phone stations during their pregnancy after a report of a cluster of childhood cancer cases near such stations. A newly published study in the British Medical Journal refutes such beliefs and has found no link to early childhood cancers and living near mobile phone masts.

22 Jun 2010

Cancer forms “intolerable burden” on the community: Health Minister

A new report reveals that here has been a 10 percent rise in cancer figures from 2006 in Australia. The figure translates to nearly 115,000 Australian cancer cases and 43,700 Australians are expected to die from the disease this year.

22 Jun 2010

Probactive Biotech, Dalat Nuclear Research Institute enter agreement to co-develop cancer drugs

Probactive Biotech, Inc., a Garden Grove, California-based corporation, has entered into an agreement with Dalat Nuclear Research Institute to co-develop a number of cancer drugs, utilizing combinations of antitumor antibodies and antitumor radioactive compounds. Antitumor antibodies have the ability to take antitumor compounds directly to the tumor sites within the body.

22 Jun 2010

Pancreatic Cancer Action Network hosts fourth annual Pancreatic Cancer Advocacy Day

The Pancreatic Cancer Action Network today hosts its fourth annual Pancreatic Cancer Advocacy Day in Washington, D.C. Nearly 500 advocates, including patients, survivors and loved ones, from across the United States will meet with members of Congress to call for congressional action to ensure progress is made against the fourth leading cause of cancer death in our country by co-sponsoring the Pancreatic Cancer Research and Education Act.

22 Jun 2010

NCI awards GeneGo Phase II SBIR grant for development of MetaMiner(Oncology) platform

GeneGo, Inc., a leading provider of databases, software and services in systems biology and chemistry, announced today that they were awarded with a Phase II SBIR grant from the National Cancer Institute (NCI) for further development of an analytical platform for translational research and data analysis in oncology.

22 Jun 2010

Pro-Pharmaceuticals receives first purchase order for DAVANAT from PROCAPS

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced it has received its first purchase order for DAVANAT from PROCAPS S.A., a large, international pharmaceutical company based in Barranquilla, Colombia. Pro-Pharmaceuticals has received a purchase order for $200,000 which will be the upfront payment for this first shipment of DAVANAT.

22 Jun 2010

Aurora Dedicated Breast MRI System installed at Ruijin Hospital, China

Aurora Imaging Technology, Inc. today announced the installation of the Aurora® Dedicated Breast MRI System in China at the world-renowned Ruijin Hospital located in Shanghai, the teaching hospital for China's top-tiered Jiao Tong University Medical School. The installation marks the first Aurora System in China.

22 Jun 2010

NIH, Wellcome Trust partner to support population-based genetic studies of disorders, communicable diseases in Africa

The National Institutes of Health, an agency of the U.S. Department of Health and Human Services, and the Wellcome Trust, a global charity based in London, today announced a partnership to support population-based genetic studies in Africa of common, non-communicable disorders such as heart disease and cancer, as well as communicable diseases such as malaria.

22 Jun 2010

Biovest targets mantle cell lymphoma as next indication for BiovaxID

Biovest International, Inc. (Other OTC:BVTI) today announced at the Active Immunotherapeutics Forum in Barcelona, Spain, that the Company is targeting mantle cell lymphoma, in addition to follicular lymphoma, as a next indication for its personalized cancer vaccine, BiovaxID. At the conference, the Company reviewed positive data from an open label Phase II mantle cell lymphoma clinical trial and reported plans to meet with the FDA later this year to discuss a pathway to seek regulatory approval for this hematological indication for which there is no current consensus standard-of-care.

22 Jun 2010

Regulus Therapeutics, sanofi-aventis partner to develop and commercialize microRNA therapeutics

Regulus Therapeutics Inc. and sanofi-aventis announced today that they have entered into a global, strategic alliance to discover, develop, and commercialize microRNA therapeutics. The alliance represents the largest microRNA partnership formed to date, valued at potentially over $750 million, and includes a $25 million upfront fee, a $10 million future equity investment subject to mutual agreement on company valuation, and annual research support for three years with the option to extend two additional years.

22 Jun 2010

Concord Medical adds two new centers by furthering partnership with Navy General Hospital

Concord Medical Services Holdings Limited, the operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced that it will add two new centers to its extensive network by furthering its partnership with the PLA Navy General Hospital, located in Beijing.

22 Jun 2010

SynCon DNA vaccine shows advantages in magnitude and breadth of immune responses in non-human primates

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the peer-reviewed journal Molecular Therapy has published a paper entitled "Comparative Analysis of Immune Responses Induced by Vaccination With SIV Antigens by Recombinant Ad5 Vector or Plasmid DNA in Rhesus Macaques." The paper, co-authored by researchers from Merck, University of Pennsylvania School of Medicine, and Inovio Pharmaceuticals, notes that significant advances in the design, formulation, and delivery of DNA plasmid-based vaccines have dramatically increased their ability to induce antigen-specific immune responses.

22 Jun 2010

Michigan State University researchers analyze histiocytic sarcomas

Michigan State University veterinarians are taking part in a two-year, $5.3 million project to analyze five cancers in dogs, research that could offer new insight into canine cancer genes and their potential impact on the human form of the disease.

22 Jun 2010

Studying cells in 3-D could help develop drugs to prevent cancer from spreading: Researchers

Showing movies in 3-D has produced a box-office bonanza in recent months. Could viewing cell behavior in three dimensions lead to important advances in cancer research? A new study led by Johns Hopkins University engineers indicates it may happen. Looking at cells in 3-D, the team members concluded, yields more accurate information that could help develop drugs to prevent cancer's spread.

22 Jun 2010

Ultrasound-guided diffuse optical tomography holds promise for ascertaining early-stage invasive breast cancer

By combining two relatively inexpensive technologies based on sound and light waves, researchers hope to lower the rate at which women undergo breast biopsies for suspicious lesions. Results of the study on ultrasound-guided optical tomography are published in the online edition and the August print issue of Radiology.

22 Jun 2010

Biodesix awarded US patent for VeriStrat serum test

Biodesix, Inc., a company developing and commercializing molecular diagnostics for personalized medicine, announced today that the United States Patent and Trademark Office has awarded to the Company patent number 7,736,905. The patent provides coverage for the Company's first product, VeriStrat®, which is used by physicians to help guide therapy for patients with advanced lung cancer. The allowed claims are directed towards the serum-based identification of patients likely to benefit from epidermal growth factor targeted therapy.

22 Jun 2010

Elevation of Smurf1 may play a role in molecular basis of PAH: Study

Pulmonary arterial hypertension (PAH) is a progressive disease, marked by shortness of breath and fatigue which can be fatal if untreated. Increased pressure in the pulmonary artery and its branches is associated with dysfunctional growth control of endothelial and smooth muscle cells leading to excessive thickening of the blood vessel wall, obliteration of the lumen and right heart failure.

22 Jun 2010

Surveillance colonoscopy is effective when targeted to high-risk patients: Study

Surveillance colonoscopy is effective and cost-effective when targeted to high-risk patients, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association Institute. However, overuse of surveillance colonoscopy could be excessively costly or even harmful.

22 Jun 2010

Gastric cancer drug market to grow from $700M in 2009 to $1.5B in 2019

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the rapid uptake and market penetration of key targeted agents, beginning with Roche/Genentech/Chugai's Herceptin, will drive the gastric cancer drug market to more than double, from $700 million in 2009 to nearly $1.5 billion in 2019.

22 Jun 2010

Pfizer to discontinue commercial availability of Mylotarg for AML in U.S.

Pfizer Inc. announced today that based on discussions with the U.S. Food and Drug Administration (FDA), it will be discontinuing commercial availability of Mylotarg® (gemtuzumab ozogamicin for Injection) (used for the treatment of relapsed acute myeloid leukemia (AML)) in the United States and that it will be voluntarily withdrawing the new drug application (NDA) for Mylotarg effective October 15, 2010.

22 Jun 2010

Cancer News and Research

Latest Cancer News and Research

No increased risk of childhood cancer if born near mobile phone stations: Study

Cancer forms “intolerable burden” on the community: Health Minister

Probactive Biotech, Dalat Nuclear Research Institute enter agreement to co-develop cancer drugs

Pancreatic Cancer Action Network hosts fourth annual Pancreatic Cancer Advocacy Day

NCI awards GeneGo Phase II SBIR grant for development of MetaMiner(Oncology) platform

Pro-Pharmaceuticals receives first purchase order for DAVANAT from PROCAPS

Aurora Dedicated Breast MRI System installed at Ruijin Hospital, China

NIH, Wellcome Trust partner to support population-based genetic studies of disorders, communicable diseases in Africa

Biovest targets mantle cell lymphoma as next indication for BiovaxID

Regulus Therapeutics, sanofi-aventis partner to develop and commercialize microRNA therapeutics

Concord Medical adds two new centers by furthering partnership with Navy General Hospital

SynCon DNA vaccine shows advantages in magnitude and breadth of immune responses in non-human primates

Michigan State University researchers analyze histiocytic sarcomas

Studying cells in 3-D could help develop drugs to prevent cancer from spreading: Researchers

Ultrasound-guided diffuse optical tomography holds promise for ascertaining early-stage invasive breast cancer

Biodesix awarded US patent for VeriStrat serum test

Elevation of Smurf1 may play a role in molecular basis of PAH: Study

Surveillance colonoscopy is effective when targeted to high-risk patients: Study

Gastric cancer drug market to grow from $700M in 2009 to $1.5B in 2019

Pfizer to discontinue commercial availability of Mylotarg for AML in U.S.

Industry Focus: Cell & Gene Therapy eBook

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Cancer News and Research

Latest Cancer News and Research

Industry Focus: Cell & Gene Therapy eBook

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Newsletters you may be interested in